CAS Number298-46-4
SynonymsTelesmin; Finlepsin; 5H-dibenzob,fazepine-5-carboxamide; 5H-Dibenz(b,f)azepine-5-carboxamide; Neurotol; Calepsin; Carbatrol; Carbelan; EINECS 206-062-7; Carbamazepine; Carbamazepin; 5H-dibenzb,fazepine-5-carboxamide; Timonil; MFCD00005073; 5H-Dibenz[b,f]azepine-5-carboxamide; Tegretol; Biston; Lexin; EPITOL; 5H-Dibenzo[b,f]azepine-5-carboxamide; Sirtal; Stazepine; 5H-DIBENZO(B,F)AZEPINE-5-CARBOXAMIDE
Molecular FormulaC15H12N2O
Molecular Weight236.27
Purity98%
Density1.3±0.1 g/cm3
Boiling Point411.0±48.0 °C at 760 mmHg
Melting Point191-192 °C (lit.)
AppearanceWhite to off-white powder
EINECS206-062-7
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 298-46-4 |
| Catalog No. | 2A-9009570 |
| Chinese Name | 卡马西平 |
| Synonyms | Telesmin; Finlepsin; 5H-dibenzob,fazepine-5-carboxamide; 5H-Dibenz(b,f)azepine-5-carboxamide; Neurotol; Calepsin; Carbatrol; Carbelan; EINECS 206-062-7; Carbamazepine; Carbamazepin; 5H-dibenzb,fazepine-5-carboxamide; Timonil; MFCD00005073; 5H-Dibenz[b,f]azepine-5-carboxamide; Tegretol; Biston; Lexin; EPITOL; 5H-Dibenzo[b,f]azepine-5-carboxamide; Sirtal; Stazepine; 5H-DIBENZO(B,F)AZEPINE-5-CARBOXAMIDE |
| Molecular Formula | C15H12N2O |
| Molecular Weight | 236.27 |
| Purity | 98 |
| Density | 1.3±0.1 g/cm3 |
| Boiling Point | 411.0±48.0 °C at 760 mmHg |
| Melting Point | 191-192 °C (lit.) |
| Appearance | White to off-white powder |
| Water Solubility | pract. insoluble |
| Storage Condition | Store at 2-8℃. |
| Packaging | III |
| Application | Carbamazepine is a pressure-sensitive sodium ion channel blocker with an IC50 of 131 μM. |
| EINECS | 206-062-7 |
| HTC | 2933990090 |
| UN(IATA) | na |
| PubChem ID | 329823092 |
| MDL Number | MFCD00005073 |
| SMILES | NC(=O)N1c2ccccc2C=Cc3ccccc13 |
| InChI | 1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18) |
| InChI Key | FFGPTBGBLSHEPO-UHFFFAOYSA-N |
| NACRES Code | NA.24 |
| UNSPSC | 41116107 |
| Hazard Symbols | 6.1(b) |
| MSDS | msds/9570_1_298_46_4.pdf |
| Bioactivity | Carbamazepine, a sodium channel blocker, is an anticonvulsant drug.Target: Sodium channelCarbamazepine inhibits the binding of [3H]batrachotoxinin A 20-α-benzoate (BTX-B) to a receptor site of voltage-sensitive sodium channel with IC50 of 131 μM, to decrease the activation of sodium channel ion flux in rat brain synaptosomes. Carbamazepine does not alter basal 125I-labeled scorpion toxin binding to synaptosomes in the absence of batrachotoxin, but when batrachotoxin (1.25 μM) added, Carbamazepine inhibits the batrachotoxin-dependent increase in scorpion toxin binding in a concentration-dependent manner with IC50 of 260 μM mediated at the alkaloid toxin binding site, none of which affects [3H]saxitoxin binding [1]. Carbamazepine at 25 mg/kg significantly increases extracellular levels of striatal and hippocampal dopamine (DA), 3,4-dihydroxyphenylalanine (DOPA), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in a dose dependent manner, while Carbamazepine at 50 mg/kg significantly decreases total levels of striatal DA and DOPA as well as hippocampal HVA, but has no effect on total levels of striatal DOPAC and HVA nor on hippocampal DA, DOPA and DOPAC [2]. Related Catalog Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> Autophagy >> Mitophagy Signaling Pathways >> Membrane Transporter/Ion Channel >> Sodium Channel Research Areas >> Neurological Disease References [1]. Willow, M. and W.A. Catterall, Inhibition of binding of [3H]batrachotoxinin A 20-alpha-benzoate to sodium channels by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol Pharmacol, 1982. 22(3): p. 627-35. [2]. Okada, M., et al., Biphasic effects of carbamazepine on the dopaminergic system in rat striatum and hippocampus. Epilepsy Res, 1997. 28(2): p. 143-53. Chemical & Physical Properties Density 1.3±0.1 g/cm3 Boiling Point 411.0±48.0 °C at 760 mmHg Melting Point 189-192 °C Molecular Formula C15H12N2O Molecular Weight 236.269 Flash Point 202.4±29.6 °C Exact Mass 236.094955 PSA 46.33000 LogP 2.67 Vapour Pressure 0.0±1.0 mmHg at 25°C Index of Refraction 1.670 InChIKey FFGPTBGBLSHEPO-UHFFFAOYSA-N SMILES NC(=O)N1c2ccccc2C=Cc2ccccc21 Storage condition 2-8°C Water Solubility pract. insoluble |
| Use of | Properties Articles284 Name carbamazepine Synonym More Synonyms Carbamazepine Biological Activity Related Catalog Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> Autophagy >> Mitophagy Signaling Pathways >> Membrane Transporter/Ion Channel >> Sodium Channel Research Areas >> Neurological Disease References [1]. Willow, M. and W.A. Catterall, Inhibition of binding of [3H]batrachotoxinin A 20-alpha-benzoate to sodium channels by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol Pharmacol, 1982. 22(3): p. 627-35. [2]. Okada, M., et al., Biphasic effects of carbamazepine on the dopaminergic system in rat striatum and hippocampus. Epilepsy Res, 1997. 28(2): p. 143-53. Chemical & Physical Properties Molecular Formula C15H12N2O Exact Mass 236.094955 PSA 46.33000 Index of Refraction 1.670 InChIKey FFGPTBGBLSHEPO-UHFFFAOYSA-N Water Solubility pract. insoluble |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information United Nations classification: inconsistent with United Nations classification standards UN number: not specified |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Calcitonin,porcine | 12321-44-7 | 2A-9009539 |
| Candesartan | 139481-59-7 | 2A-0201366 |
| Candesartan cilexetil | 145040-37-5 | 2A-9009558 |
| Capecitabine | 154361-50-9 | 2A-9009561 |
| Captopril | 62571-86-2 | 2A-9009567 |
| Carboplatin | 41575-94-4 | 2A-9009587 |
| Carvedilol | 72956-09-3 | 2A-9009611 |
| Cefaclor | 70356-03-5 | 2A-9009620 |
| Cefaclor monohydrate | 53994-73-3 | 2A-9009621 |
| Cefazolin | 25953-19-9 | 2A-9009627 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS